




ProstaLund®



ProstaLund AB
Interim report January – June 2023

Very strong sales in the quarter, + 53 %

– Fifth consecutive quarter of growth

1 April-30 June

- Net sales reached SEK 5,4 (3,5) million
- Loss after taxes SEK -4,1 (-3,7) million
- Earnings per share were SEK -0,07 (-0,07)
- Cash and equivalents were 34,4 (4,4) million

Significant events during period

- Distribution agreement signed in Poland
- Distribution agreement signed in Switzerland
- The Board decides on a rights issue
- The rights issue was subscribed to 85% and brought the company approximately SEK 34 million in capital before issue costs

1 January-30 June

- Net sales reached SEK 10,9 (8,1) million
- Loss after taxes SEK -7,3 (-5,8) million
- Earnings per share were SEK -0,10 (-0,11)

Significant events after the period

- The company decided to withdraw the 510(k) application in the USA, for the Schelin Catheter®
- The company decided that it intends to apply De Novo for Schelin Catheter®

(SEK MILLION))	Jan-June 2023	Jan-June 2022	Jan-June 2021
Net sales	11	8,1	8,5
Gross margin, %	68	76	87
Operating profit/loss	-7,2	-5,8	-3,9
Cash flow from operating activities	-6,1	-9,5	-3,2
Average number of employees	9	7	7

“The great interest in all our products, not only the stand-alone products but also CoreTherm, in several countries makes us look with confidence to the future”.


Johan Wennerholm
CEO, ProstaLund AB (publ)

Overview of the company's development

Number of CoreTherm treatments sold in the Nordic region 2018-2023




Sales development per quarter, 2020-2023




Quarterly financial performance

All amounts in SEK thousand	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Net sales	5 368	5 584	5 550	3 773	3 520	4 568
Gross profit/loss	3 605	3 795	3 902	2 791	2 469	3 711
Gross margin in %	67%	68%	70%	74%	70%	81%
Overhead costs	-7 311	-6 970	-7 334	-4 687	-5 932	-5 848
Operating profit/loss	-4 070	-3 175	-3 144	-1 987	-3 625	-2 137
Profit/loss for the period	-4 124	-3 216	-3 133	-2 117	-3 707	-2 141
Cash flow	28 041	-5 926	-3 666	11 568	-3 540	-5 326

SALES DISTRIBUTED BY CATEGORY JAN-JUN, 2023



SALES DISTRIBUTED BY CATEGORY JAN-JUN, 2022



CEO statement

It is with a smile that I write these comments. The background lies in our development for the first six months in general and the second quarter in particular. We now have five quarters behind us with growth. During each quarter we get new customers and we sign agreements in both the Nordics and in the rest of Europe, at the same time we add new interested urologists who evaluate and test our products. This means that we have a very good flow right now on the entire business, both in the short and slightly longer term. Our belief is that we have been on the right track without the numbers directly showing it. What we see now is the result of the persistent labor of recent years. I think focusing on individual quarters can be misleading and I prefer to look at developments over longer periods. If I look at the last twelve months from July 1 last year until today, we now have a turnover of over SEK 20 million for the first time. If we look at the first half of 2023, we have a sales growth of quite impressive 35 percent compared to the same period last year. What is satisfactory is that most of the quarter's growth comes from our business in the Nordics, in the first quarter it came from our business outside the Nordics. We can probably count on the fact that sales, gross margin and profit going forward will fluctuate between quarters depending on our mix of sales in and outside the Nordics, our mix of direct sales and distributor sales, exchange rates, etc.



What I am not happy about, is the cost side. What drove costs during the spring are mainly two things: our investment in our home market in the form of advertising directly towards patients, as well as increased staffing of our "patient support". The other major cost driver is and will be the regulatory work. The transition to Europe's new regulatory system (MDR) has cost several millions. According to current regulations, it has been necessary to carry out sterilization studies, validation tests and put a lot of consulting fees on regulatory specialists. Some of these are one-time costs, some of these costs are recurring in other tests and validations going forward. We will review our costs and, in some cases, slow down our expansion if it does not generate income that corresponds to the effort we invest within the foreseeable future.

Sales in the Nordics

During the second quarter, our newest private customers in Sweden, Sergelkliniken in Stockholm and Carlshamns Specialistklinik, have started producing CoreTherm treatments. At the same time, the agreement with Specialistläkargruppen in Kalmar, SLG Kalmar AB, which was signed during the first quarter, has begun to bear fruit, and in addition to this, most clinics have returned to normal levels before Covid-19. All this meant that we invoiced CoreTherm treatments for approximately SEK 9.3 million, which is an increase of +19 percent compared to last year's first six months (SEK 7.9 million). During the first half of the year we delivered 684 treatments. Growth in Denmark has been good throughout the first half of the year and we can see from the five clinics we have in Denmark, that their way of working to produce targeted care and process the queues suits our method very well. Denmark is a pioneering country in that sense.

Sales outside the Nordics

During the quarter, the Schelin Catheter® was launched in Brazil. The interest has been good and immediately after the fair we received a follow-up order from our distributor. The agreement with the Polish distributor came after they saw and heard about our product at the European Urology Congress in Milan. The first treatments using our products were carried out already in April. Interest in our stand-alone products Schelin Catheter® and CoreFlow® Soft Stent is great wherever we have been. The sale of these products in the second quarter amounted to approximately 10 percent of our total turnover and for the first half of the year that figure

was 14 percent. We have no direct comparative figures from the previous year, as we started that launch in September last year.

We have previously described how the strategy of using these products to enter new markets has so far been very successful. In June we attended the British Urology Congress, BAUS. This was the second year we participated and this time together with our distributor iUrology. Last year we were pleasantly surprised and to some extent caught off guard by the response. This year our expectations were exceeded again and we went home with more "leads" this year and we have already been invited to a seminar for 20-30 urologists after the summer. They are very interested in being able to carry out treatments under local anesthesia. But what is even more exciting is that they hardly believe us when we explain that we can treat 350 gram prostates in 15 minutes under local anesthetic. "Impossible", "Incredible if it works", "I must see that, can you send me more information" are comments we received. It feels incredibly good to know that we have a method that is one of the best in the world and we welcome them to Sweden to see a treatment with their own eyes.

Study on Schelin Catheter®

In January, the study "Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate" was published in the journal Prostate Cancer and Prostatic Diseases. At the American urology days at the beginning of May, there were two scientific presentations regarding Schelin Catheter® from Hong Kong and Italy. We get quite a few requests from different urologists who want to do studies to try Schelin Catheter® with different methods. This indicates the great interest in our catheter.

The issue

In May, the board decided to carry out an issue. A rights issue without any guarantors, this to keep issue costs down. All major owners, board and management signed. The ambition was to make it as attractive to existing shareholders, regardless of the size of one's holding. That it was subscribed to 85 percent is a statement of strength. What I also find gratifying is that over 700,000 shares were subscribed without preferential rights, and with that I welcome all new shareholders to ProstaLund. I think that this issue is largely different from the previous ones, when earlier capital acquisition was needed to complete the development of CoreTherm Eagle®, adaptation to new regulations, securing the production and logistics chain as well as patent applications, etc. Now it's all about expansion.

510(k) application

We decided to withdraw our application after a discussion with the FDA. The background was that you can choose different pathways to register a medical device in the USA. Either you point to a similar product in the USA, a so-called 510(k) application, which is an easier route, or if a similar product does not exist, you need to make a De Novo application, which requires more clinical studies and data for safety and effectiveness. We chose a 510(k) route but the FDA does not think there is a similar product on the US market. The Schelin Catheter® is unique. The FDA has not questioned our technical documentation or clinical evaluation, nor do they question the product. This means that the work that is done during the 510k application will be useful to us also in the future work, where we intend to carry out a De Novo application.

The future

Now five years of work is beginning to bear fruit. The fact that we are now working with the business in both short and slightly longer term and also with different revenue streams feels good. The great interest in all our products, not only the stand-alone products but also CoreTherm, in several countries makes us look with confidence at the future.

Johan Wennerholm
CEO

Every care has been taken in the translation of this Financial Report. In the event of discrepancies, the Swedish original will supersede the English translation

Business overview

The Company in brief

ProstaLund is a Swedish company with headquarters in Lund. The company's registration number is 556745-3245. ProstaLund is a Swedish public limited company that was registered at the Swedish Companies Registration Office on December 4, 2007. The board has its registered head office in the municipality of Lund and operations are based in Sweden. The company's office address is Scheelevägen 19 in Lund with telephone number 046-12 09 08. The company's website is www.prostalund.se. The company is a reconciliation company and its share register is kept by Euroclear Sweden AB. In addition to ProstaLund, which is the parent company, the group includes the wholly owned subsidiaries Nordisk Medicin & Teknik AB ("NMT") and the American subsidiary CoreTherm® Medical Inc. ("CMI").

Introduction to the Company's operations

The company develops, markets and sells products in urology. The majority of the sales are made through recurring sales of disposable catheters, antennas and other accessories that are used together with the Company's platform in the treatment of BPH/BPE.

The company has a treatment concept (CoreTherm® Concept) for individually adapted heat treatment for benign prostate enlargement, also called BPE or BPH, which mainly affects men over 50 years of age.

In recent years, the company has developed a new platform, CoreTherm® Eagle, which received market approval through a CE marking based on the EU's medical technology regulations (MDR) in February 2023.

The platform now has, among other things, a built-in computer, temperature reading in real time, storage of patient data and built-in recommendations for treating doctors. The company believes that CoreTherm® Concept constitutes one of the market's best treatments against BPH/BPE with regard to parameters such as treatment results, possibility to treat regardless of prostate size, retreatment frequency, treatment time, fewer complications compared to surgical intervention, learning time for treating doctors and cost of a treatment. CoreTherm® Concept consists of several patented and unique inventions where the machine's treatment control is based on 25 years of research and clinical experience.

At the same time, the Company has two independent products, Schelin Catheter® and CoreFlow® Soft Stent, which were launched in Europe in September 2022, with very good results. These two products have shown rapid growth and corresponded to approximately 12 percent of sales during the fourth quarter of 2022 as well as approximately 18 percent during the first quarter of 2023 and 10 percent in the second quarter of 2023 respectively. It is the Company's opinion that the products are unique because there are no similar products on the market as a result of the Company holding patents for both products in the markets in which the Company operates.

The company's product range is CoreTherm® Concept, which consists of anesthetic catheters (Schelin Catheter®), treatment catheters (CoreTherm® Catheter) and aftercare catheters (CoreFlow® Soft Stent).

Schelin Catheter® and CoreFlow® Soft Stent are also sold for use in other treatment methods outside of the CoreTherm® Concept. The company also sells the urine flow meter Oruflow.

CoreTherm® Concept – Treatment concept

CoreTherm® Concept is a patented and individually adapted treatment concept of BPH/BPE through heat. CoreTherm® Concept is used today primarily in public hospitals and private clinics in the Nordics. In 2021, the Company had approximately 20 percent market share of the treatments performed in Sweden. The treatment is evidence-based and has the same end result as surgery. The concept has a number of advantages:

- The size of the prostate does not limit the method
- The treatment is performed under local anesthesia, to be compared with full anesthesia during surgery
- Maximum treatment time is 15 min

During a CoreTherm® Concept treatment, the temperature is measured in real time. The treatment effect can thus be calculated continuously and with the help of the temperature monitoring the responsible doctor or nurse can control the treatment. The treatment takes a maximum of 15 minutes and the entire visit to the reception takes around 1 hour in total.

Schelin Catheter® - Injection tool

Schelin Catheter® is a patented and unique product that has a built-in needle in the catheter intended for intraprostatic and periprostatic injection of drugs directly into the prostate. With the Schelin Catheter®, anesthetics and adrenaline are administered to manage pain and prostatic blood flow during a CoreTherm® Concept treatment of BPH/BPE, and the catheter thus has a central role in the development of the treatment concept.

The product can also be used in other contexts, for example before local anesthesia and other treatment procedures regarding ailments in the prostate, where drugs need to be administered into the prostate sterilely. Since the launch, September 2022, the Company has experienced greatly increased demand for the product in Europe.

CoreFlow® Soft Stent – Aftercare product

CoreFlow® Soft Stent is a patented and unique product. The product is a hybrid between a catheter and a stent. The product has many uses:

The product can be used as a disposable product after the BPH/BPE treatment regardless of the treatment method. The product can also be used as a diagnostic tool and simulate treatment results of an invasive measure against obstruction, microwave therapy (TUMT) or transurethral resection (TURP). The product is also an alternative to indwelling catheter (KAD) in case of urinary retention, which enables self-drainage and reduces the risk of urinary tract infection. CoreFlow® Soft Stent can partially replace urodynamic examinations, as well as be used where said examinations are not applicable.

This product is also used outside of the CoreTherm® Concept treatment and is sold as a stand-alone product in Europe together with the Schelin Catheter® (see above).

Financial information

Company information

ProstaLund AB (publ), corporate identity 556745-3245, with its registered head office in Lund is the parent company of the ProstaLund Group. The address of the head office is Scheelevägen 19, 223 70 Lund. Wholly owned subsidiaries are Nordisk Medicin & Teknik AB and CoreTherm®Medical Inc (USA).

Shares

ProstaLund is listed on the Nasdaq First North Growth Market. The company is traded under the ticker name PLUN and the ISIN code SE0002372318. Certified Adviser is Västra Hamnen Corporate Finance AB.

The number of shares at the end of the period was 75,861,146. and the quota value was SEK 0.1 per share. A further 727,591 shares were registered on 07/03/2023. All shares are of the same type and have the same voting rights.

Scope of the report

This interim report covers the period from 1 January 2023 to 30 June 2023. The comparative information in the report refers to the corresponding period in 2022, unless otherwise stated. All information in the report refers to the ProstaLund Group, unless it is explicitly stated that the information refers to the parent company ProstaLund AB (publ).

Sales and earnings – second quarter

Net sales amounted to SEK 5,368 (3,520) thousand, which was a 53 percent increase compared with the same period last year. The increase is mainly due to a 37 percent increase in sales for treatment catheters and some sales of the stand-alone products. The new clinics the company entered into agreements with during the first quarter, began treating patients during the second quarter.

The operating loss was SEK -4,070 (-3,625) thousand. Loss after tax came in at SEK -4,124 (-3,707) thousand.

Sales and earnings

Net sales amounted to 10,952 (8,088) thousand, which was an increase of 35 percent compared to the previous year. The change is, among other things, due to new agreements with clinics in Sweden, growth in Denmark and sales of stand-alone products outside the Nordic region. The operating profit amounted to -7,245 (-5,762) thousand. The deterioration in earnings

is partly due to a deterioration in the gross margin, which is mainly due to the negative currency effect of the USD, partly due to external costs for marketing and regulatory costs in connection with the transition to the medical technology regulatory framework MDR for Europe. Loss after tax amounted to -7,339 (-5,848) thousand.

Investments – second quarter

Investments in property, plant & equipment amounted to SEK 121 (-) thousand. Investments in intangible assets amounted to SEK 692 (909) thousand, which mainly relate to the company's new platform and patents.

Investments

Investments in property, plant & equipment amounted to SEK 121 (50) thousand. Investments in intangible assets amounted to SEK 1,007 (4,002) thousand.

Financial position and financing – second quarter

Cash flow from current operations amounted to -580 (-4,464) thousand.

The company took out a short-term loan of SEK 1 million in May, without collateral, from the owners, Mats Alyhr and Sonny Schelin. Market interest charged the quarter with SEK 11,000. The short-term loan of SEK 1 million was repaid on June 30th.

A rights issue was carried out during the month of June and provided the company with approximately SEK 30.7 million in new capital after deduction for issue costs. Cash and cash equivalents at the end of the period amounted to SEK 34,390 (4,373) thousand.

Financial position and financing

Cash flow from operating activities during the first half of the year amounted to -6,091 (-9,547) thousand. The cash flow has mainly been affected by the negative result and increased capital tied up in the form of increased inventory. Lead times on components increased significantly and to ensure being able to deliver to customers, a decision was made on a buffer stock.

Equity amounted to SEK 63,890 (27,799) thousand and the equity ratio amounted to 82 (72) percent. Cash and cash equivalents at the end of the period amounted to SEK 34,390 (4,373) thousand.

Organisation

The number of people employed was 10 (7) at the end of the period. The employees included 6 (4) women and 4 (3) men. The average number of employees was 9. The number of consultants was 5.

Research and development

Development work is conducted in-house in collaboration with technical consultants and external clinics. The development work is focused on new development and further refinement of the current product portfolio.

Insurance

ProstaLund has a standard corporate insurance which also includes product liability. The insurance is subject to ongoing review. The Board of Directors assesses that the corporate insurance is adapted to the current scope of operations.

Disputes

ProstaLund is not a party in any legal disputes or arbitrations. The Board of Directors is not aware of any circumstances that could lead to any such legal processes being imminent.

Risk factors

ProstaLund is affected by a number of risks whose effects could have a negative impact on its future, earnings or financial position. The latest annual report and prospectus, which is available on the company's website www.prostalund.se, contains a description of the risk factors. The risk factors that are judged to be of the greatest importance are listed below, in no particular order:

- Depending on financing
- Depending on key personnel
- Regulatory approvals
- Product liability
- Currency risk
- Competition
- Disputes
- Changes in legislation

Prerequisites for continued operation

This financial information has been prepared based on the assumption of continued operations. The company has historically reported losses. In preparing the report, management has based its assumptions on existing cash and cash equivalents, increased sales and the possibility of other financing.

When estimating future expenses, management has taken into account that certain expenses are under management's control and can thus be eliminated or postponed to the future. Management is aware that there are uncertainties in the estimation of future cash flows as well as uncertainties in the financing of operations.

If the Group for some reason can't continue to operate, it may affect the Group's ability to realize the assets carrying amounts, especially related to capitalized expenses for development work, and to pay debts at a normal rate and to the amounts included in the Group's interim report.

Transactions with related parties

Agreement with board members

The Company has entered into consulting agreements with some of the Company's Board members. The consulting agreements regulate the board members' performance of assignments that cannot be considered to be tasks that are normally incumbent on a board member. The fee for work according to the consulting agreement amounts to SEK 1,800 per hour. Others on the Board and the Company's CEO must approve such work before it is performed.

Royalty agreement

The company has previously entered into a royalty agreement with Schelin Medicin AB regarding the rights to the products Coreflow® Soft Stent and the Schelin Catheter®. The agreement means that two (2) percent of the invoiced amount for these products must be paid in royalties to Schelin Medicin AB, provided that the company reports a profit and that a patent has been granted. The royalty can amount to a maximum of SEK 4 million per year and a maximum of SEK 20 million in total. The agreement shall cease to apply when an amount of SEK 20 million has been paid to Schelin Medicin AB.

Valuation of intangible assets

The reported capitalized expenses for development work are subject to management's impairment test. The most critical assumption, evaluated by management, relates to whether the intangible asset is expected to generate future economic benefits, which at least correspond to the carrying amount of the intangible asset. Management's assessment is that the expected future cash flows are sufficient to justify the

carrying amount of the intangible asset, which is why no write-down has been made. However, the valuation is based on and dependent on the conditions for continued operation.

Remuneration policy

The guiding principle is that ProstaLund will offer its management and key personnel competitive remuneration based on the market situation, the company's performance, and individual performance. The design of the remuneration policy shall ensure that the management and key personnel and the shareholders have common goals.

Annual report

The annual report for 2022 was published on April 4 2023. The annual report is available on the company's website www.prostalund.se.

Annual General Meeting

The Annual General Meeting for 2022 was held on May 4th 2023 in Lund.

Upcoming financial information

- 2023-10-25 Interim report Jul-Sep 2023
- 2024-02-16 Year-end report 2023

Accounting policies

This report has been prepared in accordance with the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's general advice. Accounting principles and calculation methods applied are in accordance with the accounting principles used in the preparation of the most recent annual report.

Audit

This report has not been subject to review by the company's auditors.

ProstaLund AB (publ)
Lund 14 juli 2023

The Board of ProstaLund

FOR QUESTIONS ABOUT THIS REPORT, PLEASE CONTACT:

Johan Wennerholm, CEO, ProstaLund AB

+46 (0)730-42 99 97 | E-post: johan.wennerholm@prostalund.com

PUBLICATION

This information is information that ProstaLund AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:15 a.m. CET July 14th 2023

ProstaLund is listed on the Nasdaq First North Growth Market. The Company is traded under the ticker name PLUN and ISIN code SE0002372318.

Certified Advisor is Västra Hamnen Corporate Finance AB.

Consolidated Income Statement in Summary

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Operating income					
Net sales	5 368	3 520	10 952	8 088	17 411
Cost of goods sold	-1 763	-1 051	-3 552	-1 908	-4 538
Gross profit	3 605	2 469	7 400	6 180	12 873
Sales & Marketing expenses	-4 360	-3 916	-8 530	-7 534	-14 288
Administrative expenses	-1 608	-1 220	-3 314	-2 394	-5 513
Research and development costs	-1 343	-796	-2 437	-1 852	-4 000
Other operating income	-	-	-	-	393
Capitalized development expenditure	-364	-162	-364	-162	-358
Operating profit/loss	-4 070	-3 625	-7 245	-5 762	-10 893
Profit/loss from financial items					
Interest income and similar profit/loss items	-	-	1	-	2
Interest expenses and similar profit/loss items	-54	-82	-95	-86	-207
Profit/loss after financial items	-4 124	-3 707	-7 339	-5 848	-11 098
Tax expenses	-	-	-	-	-
Profit/loss for the period	-4 124	-3 707	-7 339	-5 848	-11 098
Share attributable to parent company shareholders	-4 124	-3 707	-7 339	-5 848	-11 098
Per share data	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Earnings per share, SEK (basic and diluted)	-0,07	-0,07	-0,12	-0,11	-0,21
Equity per share, SEK	0,84	0,54	0,51	0,64	0,73
Equity-asset ratio, %	82%	72%	82%	72%	82%
Number of outstanding shares	75 861 146	51 525 365	75 861 146	51 525 365	57 193 154
Average number of outstanding shares	63 415 818	51 525 365	60 304 486	51 525 365	53 886 944

Definitions of financial ratios

Earnings per share. Profit/loss for the period divided by average weighted number of shares

Equity-asset ratio. Equity divided by total assets.

Equity per share. Equity divided by number of shares at the end of the period.

Quarterly financial performance

All amounts in SEK thousand	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Net sales	5 368	5 584	5 550	3 773	3 520	4 568
Gross profit/loss	3 605	3 795	3 902	2 791	2 469	3 711
Gross margin in %	67%	68%	70%	74%	70%	81%
Overhead costs	-7 311	-6 970	-7 334	-4 687	-5 932	-5 848
Operating profit/loss	-4 070	-3 175	-3 144	-1 987	-3 625	-2 137
Profit/loss for the period	-4 124	-3 216	-3 133	-2 117	-3 707	-2 141
Cash flow	28 041	-5 926	-3 666	11 568	-3 540	-5 326

Consolidated Balance Sheet in Summary

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
Assets				
Intangible assets	25 915	24 385	25 227	24 934
Property, plant & equipment	445	395	381	419
Inventories	13 748	6 421	11 038	9 187
Trade receivables	1 527	1 778	1 541	2 816
Other receivables	1 986	1 034	1 115	1 412
Cash and cash equivalents	34 390	4 373	6 349	12 275
Total assets	78 011	38 386	45 651	51 043
Equity and liabilities				
Equity	63 890	27 799	38 460	41 686
Interest-bearing liabilities, longterm	1 133	1 533	1 233	1 333
Current interest-bearing liabilities	400	3 400	400	400
Trade payables	10 859	2 449	4 099	6 298
Other liabilities	1 729	3 205	1 459	1 326
Total equity and liabilities	78 011	38 386	45 651	51 043

Consolidated statement of changes in equity

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
Opening balance	41 686	35 456	41 686	35 456
New share issues	32 669	-	-	19 837
Costs of new share issues	-3 135	-	-	-1 378
Profit/loss for the period	-7 339	-5 848	-3 216	-11 098
Other comprehensive income for the	9	-1 809	-10	-1 131
Closing balance	63 890	27 799	38 460	41 686

Cash Flow Analysis in Summary

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Profit/loss after financial items	-4 123	-3 707	-7 339	-5 848	-11 098
Adjustments for non-cash items	81	-1 422	131	-1 717	-910
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	-4 042	-5 129	-7 208	-7 565	-12 008
Changes in working capital	3 462	665	1 117	-1 982	-4 194
Cash flow from operating activities	-580	-4 464	-6 091	-9 547	-16 202
Capitalization of development expenditure	-692	-909	-1 007	-4 002	-4 607
Acquisition/disposal of property, plant & equipment	-121	-	-121	-50	-147
Förvärv/Avyttring av finansiella anläggningstillgångar	-	-	-	-	-
Cash flow from investing activities	-813	-909	-1 128	-4 052	-4 754
New share issue	32 669		32 669		19 837
Transaction costs attributable to new share issue	-3 135		-3 135		-1 378
Change in bank overdraft facilities	1 000	2 000	1 000	5 000	5 000
Change in bank overdraft facilities	-1 100	-167	-1 200	-267	-3 467
Cash flow from financing activities	29 434	1 833	29 334	4 733	19 992
Total cash flow for the period	28 041	-3 540	22 115	-8 866	-964
Cash and cash equivalents at start of period	6 349	7 913	12 275	13 239	13 239
Cash and cash equivalents at end of period	34 390	4 373	34 390	4 373	12 275

Income Statement - Parent Company

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Operating income					
Net sales	5 335	3 414	10 853	7 882	17 179
Cost of goods sold	-1 733	-986	-3 488	-1 817	-4 430
Gross profit	3 602	2 428	7 365	6 065	12 749
Sales & Marketing expenses	-4 309	-3 875	-8 415	-7 454	-14 253
Administrative expenses	-1 608	-1 221	-3 314	-2 395	-5 513
Research and development costs	-1 343	-796	-2 437	-1 852	-4 000
Other operating income	-	-	-	-	433
Capitalized development expenditure	-364	-163	-364	-163	-358
Operating profit/loss	-4 022	-3 626	-7 165	-5 798	-10 942
Profit/loss from financial items					
Interest income and similar profit/loss items	-	-	1	-	2
Interest expenses and similar profit/loss items	-52	-82	-93	-86	-1 562
Profit/loss after financial items	-4 074	-3 708	-7 257	-5 884	-12 502
Tax expenses	-	-	-	-	-
Profit/loss for the period	-4 074	-3 708	-7 257	-5 884	-12 502

Balance Sheet - Parent Company

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
Assets				
Intangible assets	25 915	24 385	25 227	24 934
Property, plant & equipment	445	395	381	419
Financial assets	464	464	464	464
Inventories	13 676	6 388	10 979	9 170
Trade receivables	1 517	1 745	1 515	2 816
Receivables from group companies	-	40	62	0
Other receivables	1 879	1 116	1 124	1 408
Cash and bank balances	34 062	4 119	5 932	11 862
Total assets	77 958	38 652	45 684	51 073
Equity and liabilities				
Equity	64 269	29 844	38 500	41 684
Interest-bearing liabilities, longterm	1 133	1 533	1 233	1 333
Current interest-bearing liabilities	400	3 400	400	400
Liabilities to group companies	-	-	0	64
Trade payables	10 440	2 441	4 058	6 295
Other liabilities	1 716	1 434	1 493	1 297
Total equity and liabilities	77 958	38 652	45 684	51 073